| abstract |
The present invention provides a compound of formula I or a pharmaceutically acceptable salt thereof, wherein R 1 , Q, S, T, U, V and R 2 are as defined herein. provide. The invention also provides a pharmaceutical composition comprising a compound of formula I as defined herein or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier, diluent or excipient. The present invention also provides a method of inhibiting MMP-13 enzyme in an animal comprising administering to the animal a compound of formula I or a pharmaceutically acceptable salt thereof. The present invention is a method of treating a disease mediated by an MMP-13 enzyme in a patient, comprising administering to the patient a compound of formula I, or a pharmaceutically acceptable salt thereof, alone or in a pharmaceutical composition. It also provides a way to do this. The present invention relates to heart disease, multiple sclerosis, osteoarthritis and rheumatoid arthritis, arthritis other than osteoarthritis or rheumatoid arthritis, heart failure, inflammatory bowel disease, heart failure, age-related macular degeneration, chronic obstruction A method for the treatment of diseases such as pulmonary diseases, asthma, periodontal disease, psoriasis, atherosclerosis and osteoporosis, comprising a compound of formula I or a pharmaceutically acceptable salt thereof, alone or in a pharmaceutical composition Also provided is a method comprising administering to a patient. The present invention also provides a combination comprising a compound of formula I or a pharmaceutically acceptable salt thereof together with another pharmaceutically active ingredient as described herein. |